---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-007048"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:45:58.866478+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Voyager Q1 net loss $21.3M, inked Novartis deal for $54M upfront

## Summary
- Q1 net loss $21.3M; collaboration revenue $0.7M (down from $6.5M YoY); cash $166.8M, runway into 2024.
- Novartis license option: $54M upfront, up to $1.5B milestones for TRACER capsids on up to 5 CNS targets.
- Alfred Sandrock appointed CEO (March 2022); Robin Swartz promoted to COO.
- TRACER AAV9 capsid yields 50-60x better brain transduction in mice/macaques vs AAV9; AAV5 capsid 20x vs AAV9.
- Preclinical data: vectorized HER2 antibody reduces tumor burden; GBA1, SOD1, anti-tau programs advancing.

## SEC filing metadata
- accession: 0001558370-22-007048
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837022007048/0001558370-22-007048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837022007048/vygr-20220504x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-007048
- JSON: https://secwatch.observer/filing/0001558370-22-007048.json
- Plain text: https://secwatch.observer/filing/0001558370-22-007048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.